Message from the Managing Director’s Desk

As we endure these testing times, I take this opportunity to share some perspectives and developments within our company which will drive our strategies and growth in the years ahead.

While we continue to rise above the challenges in the pharmaceutical industry, we have made a paradigm shift in our operations in the US and Canada, with consolidation of Lambda Therapeutic Research’s Toronto, Canada clinic and bioanalytical laboratory into Novum operations. Canada’s state-of-the-art facility offers niche Pharmacokinetics (PK), Late Phase and Complex Bioanalytical services, which we feel would be a comprehensive value-add in your Drug development programs. By embracing the Novum brand, with its nearly fifty year history, as across our North American operations, we will deliver an enhanced, more seamless suite of services to our clients.

In the past year, we have continued our impeccable regulatory track record of clearing various international regulatory inspections across our units globally. We have also further enhanced our global clinical trial management capabilities by investing in scientific talent and expanding our geographical breadth of clinical sites globally. We continue to serve all our clientele through existing early and late Phase service offerings successfully.

During these unprecedented times of COVID-19, we are addressing the challenges through robust and proactive measures under Novum’s COVID-19 Protocol. Our intention is to continue delivering services at the highest standards to our clients while mitigating the risks of COVID-19 for all our stakeholders.

I am confident that our positive energy, resolute integrity and unwavering commitment will ensure we continue to meet and exceed client expectations all the time and every time.

Stay safe, stay healthy.

Bindi Chudgar
Managing Director